COVID-19: All Coverage
“I think there is a silver lining to [the J&J] vaccine that a lot of people don’t see,” says David Martinez, a UNC Gillings School of Public Health postdoctoral fellow. He researches immune responses to COVID-19 vaccines. Several researchers report early hints that, while J&J offers less protection up front, it may remain effective in the body for much longer.
A group of nine researchers led by UNC-Chapel Hill from the Rapidly Emerging Antiviral Drug Development Initiative (READDI) is the winner of the institute’s Forethought Research Collaboration Challenge, securing them with $5 million to help accelerate the production of antiviral drugs in the future.
The public health response to the COVID-19 pandemic was uniquely widespread and rapid, with great potential for human rights impacts around the world. Faculty, students and alumni from UNC’s Gillings School of Global Public Health created a database to monitor potential rights violations.
COVID-19 is impacting people in a variety of ways. Those hard of hearing that use cochlear implants struggle to understand practitioners more when they use masks and face shields. The study suggests doctors use N95 masks and goggles for eye protection.
Andrea Hussong, professor and associate director of clinical psychology in the department of psychology and neuroscience, has been studying the impact of COVID-19 on adolescents’ mental health. Learn more about her work in this special Q&A for University Research Week.
Researchers at UNC, Duke University, and the University of Pennsylvania created an mRNA vaccine that proved effective against several different types of coronavirus. Their goal? A universal vaccine.
A new analysis by Innovate Carolina shows that in 2021 UNC-affiliated startups have generated more than $14 billion in revenue and created more than 12,000 jobs across North Carolina.
UNC School of Education researchers have won more than $3.5 million in NSF awards to pursue projects on STEM learning and learning in the COVID-19 pandemic. They hope their findings will inform instructional practices and policies, including ones that can better extend educational opportunity to underserved students.
David Martinez, a postdoctoral fellow at the UNC Gillings School of Global Public Health, began designing a vaccine against SARS-like viruses in April 2020 as the pandemic took hold in the U.S. “I thought, we need to start thinking about preventing SARS 3,” he says.
UNC School of Medicine professor David Wohl analyzed reinfection data and discovered people who were vaccinated were much less likely to get COVID-19 a second time. Of the 10,000 people who were re-infected, 1% of people who contracted the virus, only 200 were vaccinated.